Similarly to syndecan-1, the expression of syndecan-2 is dependent on the ER status and on insulin-like growth factor receptor (IGFR) and EGFR; as well, it affects the malignant behaviour of BC cells [41]. This evidence concerns the gene SDC1 and breast cancer.